Labs was QuidelOrtho’s largest revenue line in fiscal 2024, bringing in $1.43B of $2.78B (51%).
| Business Unit | FY 2021 | FY 2022 | FY 2023 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|
| Point Of Care | $1.39B | $1.45B | $1.96B | $892.40M | $694.60M |
| Labs | $50.90M | $44.80M | $820.20M | $1.43B | $1.43B |
| Immunohematology | — | — | $296.80M | $512.00M | $522.00M |
| Donor Screening | — | — | $97.00M | $135.90M | $115.10M |
| Molecular Diagnostics | $223.00M | $200.50M | $96.70M | $31.70M | $24.00M |
| Total | $1.66B | $1.70B | $3.27B | $3.00B | $2.78B |
QuidelOrtho brought in $2.78B from its five revenue lines in fiscal 2024, the year ended December 29, 2024. That was down 7.2% from $3.00B in fiscal 2023. Labs was the largest at $1.43B (51.3%), ahead of Point Of Care at $694.60M (25.0%) and Immunohematology at $522.00M (18.8%). The other two revenue lines brought in $139.10M combined.
Compared with fiscal 2023, Immunohematology grew fastest, up 2.0% to $522.00M, while Point Of Care fell the most, down 22.2% to $694.60M.
QuidelOrtho began breaking out Immunohematology in fiscal 2023 and Donor Screening in fiscal 2023.
North America was QuidelOrtho’s largest segment in fiscal 2024, bringing in $1.62B of $2.78B (58%).
| Segment | FY 2021 | FY 2022 | FY 2023 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|
| North America | $1.46B | $1.50B | $2.54B | $1.88B | $1.62B |
| Other | $45.70M | $70.80M | $302.70M | — | — |
| China | $62.40M | $58.00M | $220.00M | $310.10M | $325.00M |
| Jpac | — | — | — | $272.70M | $279.40M |
| Latin America | — | — | — | $210.60M | $222.90M |
| Emea | $92.90M | $69.60M | $206.80M | $327.30M | $335.80M |
| Total | $1.66B | $1.70B | $3.27B | $3.00B | $2.78B |
QuidelOrtho brought in $2.78B from its five segments in fiscal 2024, the year ended December 29, 2024. That was down 7.2% from $3.00B in fiscal 2023. North America was the largest at $1.62B (58.2%), ahead of Emea at $335.80M (12.1%) and China at $325.00M (11.7%). The other two segments brought in $502.30M combined.
Compared with fiscal 2023, Latin America grew fastest, up 5.8% to $222.90M, while North America fell the most, down 13.7% to $1.62B.
QuidelOrtho began breaking out Jpac in fiscal 2023 and Latin America in fiscal 2023. QuidelOrtho stopped reporting Other as a separate segment after fiscal 2023, when it brought in $302.70M.
Domestic was QuidelOrtho’s largest region in fiscal 2024, bringing in $1.57B of $2.78B (56%).
| Geography | FY 2023 | FY 2023 | FY 2024 |
|---|---|---|---|
| Domestic | $2.45B | $1.83B | $1.57B |
| Foreign | $814.30M | $1.17B | $1.21B |
| Total | $3.27B | $3.00B | $2.78B |
QuidelOrtho brought in $2.78B from its two regions in fiscal 2024, the year ended December 29, 2024. That was down 7.2% from $3.00B in fiscal 2023. Domestic was the largest at $1.57B (56.4%), ahead of Foreign at $1.21B (43.6%).
Compared with fiscal 2023, Foreign grew 3.9% to $1.21B, while Domestic fell 14.2% to $1.57B.
QuidelOrtho (QDEL) reports its revenue by business unit, by segment and by geography. In fiscal 2024, Labs was its largest revenue line, bringing in $1.43B (51.3% of the total), followed by Point Of Care at $694.60M (25.0%).
Labs was QuidelOrtho's largest revenue line in fiscal 2024, bringing in $1.43B, or 51.3% of the $2.78B total across its five revenue lines.
North America was QuidelOrtho's largest segment in fiscal 2024, bringing in $1.62B, or 58.2% of the $2.78B total across its five segments.
Domestic was QuidelOrtho's largest region in fiscal 2024, bringing in $1.57B, or 56.4% of the $2.78B total across its two regions.
Among QuidelOrtho's revenue lines that make up at least 2% of revenue, Immunohematology grew fastest in fiscal 2024, up 2.0% from $512.00M to $522.00M.
Every figure comes from QuidelOrtho's annual financial filings, as reported. Each line keeps the name QuidelOrtho gives it, and years follow its fiscal calendar.
QuidelOrtho's revenue by business unit goes back to fiscal 2021, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.